Effects of extended access to high versus low cocaine doses on self-administration, cocaine-induced reinstatement and brain mRNA levels in rats.
BACKGROUND
The investigation of rodent cocaine self-administration (SA) under conditions that promote escalating patterns of intake may provide insight into the loss of control over drug use that is central to human addiction.


OBJECTIVE
This study examines the effects of daily long-access (LgA) SA of high or low cocaine doses on drug intake, extinction, reinstatement, and brain mRNA levels.


METHODS
Three groups of male Sprague-Dawley rats were trained to self-administer cocaine during multiple-dose sessions. Short-access (ShA) rats were tested daily for multi-dose SA then remained in the chambers for 7 h with no cocaine available. LgA rats had access to low (0.5 mg/kg per infusion; LgA-LD) or high (2.0 mg/kg per infusion; LgA-HD) cocaine doses for 7 h after multi-dose SA. After 14 days, responding was extinguished, cocaine-induced reinstatement was determined, and preproenkephalin (ppENK), preprodynorphin (ppDYN), corticotropin releasing factor (CRF) and dopamine D(2) receptor (D(2)R) mRNA levels were measured in various brain regions using a quantitative solution hybridization RNase protection assay.


RESULTS
Whereas SA was not altered in ShA rats and only increased during the "loading phase" in LgA-LD rats, a general escalation of intake was found in LgA-HD rats. LgA, particularly LgA-HD, rats were more susceptible to reinstatement than ShA rats. Caudate-putamen ppENK and nucleus accumbens D(2)R mRNA levels were elevated in LgA-HD rats. Overall, D(2)R mRNA levels were positively correlated with reinstatement.


CONCLUSIONS
The escalation of cocaine SA under LgA conditions is dose-dependent and is associated with heightened susceptibility to drug-induced relapse. The characterization of neurobiological alterations that accompany escalated SA should facilitate the identification of mechanisms underlying the onset of human addiction.
Mantsch
John R
JR
The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, USA. john.mantsch@marquette.edu
Yuferov
Vadim
V
Mathieu-Kia
Anne-Marie
AM
Ho
Ann
A
Kreek
Mary Jeanne
MJ
D000818:Animals; D016739:Behavior, Addictive / Q000523:psychology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003042:Cocaine / Q000008:administration & dosage*; D019970:Cocaine-Related Disorders / Q000523:psychology; D003346:Corticotropin-Releasing Hormone / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004399:Dynorphins / Q000235:genetics / Q000378:metabolism; D004745:Enkephalins / Q000235:genetics / Q000378:metabolism; D005108:Extinction, Psychological / Q000187:drug effects; D008297:Male; D018847:Opioid Peptides / Q000235:genetics / Q000378:metabolism; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000235:genetics / Q000378:metabolism; D012008:Recurrence; D012646:Self Administration; D013997:Time Factors
D004745:Enkephalins; D018847:Opioid Peptides; D011498:Protein Precursors; D012333:RNA, Messenger; D017448:Receptors, Dopamine D2; C036448:pre-prodynorphin; D004399:Dynorphins; D003346:Corticotropin-Releasing Hormone; C033660:preproenkephalin; D003042:Cocaine